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Abstract
Background The purpose of this study was to evaluate the
safety and effectiveness of iloperidone for the prevention
of relapse in schizophrenia.
Methods Study subjects were adults with schizophrenia
who started on oral open-label iloperidone titrated to an
initial target dose of 12 mg/day (6 mg twice daily) and
then stabilized on a flexible-dose iloperidone regimen
(range 8–24 mg/day) for up to 24 weeks. Subjects meeting
stabilization criteria then entered the relapse-prevention
phase and were randomized 1:1 in a double-blind fashion
to continue with iloperidone or placebo withdrawal for up
to 26 weeks or until meeting relapse or other withdrawal
criteria.
Results A total of 303 subjects were randomized to the
relapse-prevention phase; 153 continued to receive
iloperidone, and 150 were withdrawn to placebo. The
modal total daily dose for iloperidone in all phases of the
study was 12 mg/day. The pre-defined unblinded interim
analysis upon reaching 68 relapse events confirmed the
hypothesis that iloperidone (n = 97) was more effective
than placebo (n = 96) in preventing relapse events, and the
trial was stopped early. The estimated relapse rates were
63.4 % (Kaplan–Meier [KM] estimate) for placebo com-
pared with 20.4 % (KM estimate) for those continuing to
receive iloperidone (log rank test: p\ 0.0001). The mean
time to relapse was 71 days for placebo and 139 days for
iloperidone (hazard ratio 4.7; 95 % confidence interval
2.7–8.3; p\ 0.0001). The safety profile observed in pre-
vious short-term studies was also reaffirmed in this main-
tenance treatment setting. The most common treatment-
emergent adverse events (TEAEs) in the stabilization phase
were dizziness (11.6 %), somnolence (8.3 %), and dry
mouth (6.8 %). Rates of reported extrapyramidal disorder
or akathisia during stabilization were 2.5 and 3.7 %,
respectively.
Conclusions Flexible dosing of iloperidone for mainte-
nance-phase therapy, with a modal dose of 12 mg/day was
effective in preventing relapse in subjects previously sta-
bilized on iloperidone. The adverse event profile for
iloperidone was consistent with other studies, and the low
extrapyramidal symptom and akathisia burden during sta-
bilization was sustained during the course of the study.
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Key Points
Iloperidone is an effective antipsychotic for the
prevention of relapse during maintenance treatment
of schizophrenia in patients previously stabilized on
iloperidone.
The approved dose range of iloperidone for acute
treatment is 12–24 mg/day given twice a day; in this
relapse-prevention trial, most subjects were treated
successfully with a dose between 12 and 16 mg/day.
The adverse event profile for iloperidone in this
study was consistent with those in the fixed-dose
acute iloperidone studies, showing very low
propensity to cause extrapyramidal symptoms or
akathisia.
1 Introduction
Iloperidone is a second-generation ‘‘atypical’’ antipsy-
chotic currently available as an oral formulation. Its pri-
mary mechanism of action is combined D2/5HT2A
antagonism, with greater affinity for the 5HT2A receptor
than for the D2 receptor [1]. Whereas iloperidone shares a
high affinity for both D2 and 5HT2A receptors, it has a
unique receptor-binding profile that includes very strong
affinity for the noradrenergic alpha 1 (NEa1) receptor [2].
The tolerability profile of iloperidone is most notable for a
very low propensity to cause either antipsychotic-induced
akathisia or antipsychotic-induced extrapyramidal symp-
toms (EPS). The low propensity for akathisia or EPS is
seen across the entire therapeutic dose range, and the need
for anticholinergics or other anti-EPS or anti-akathisia
therapies is relatively infrequent [3–7].
Iloperidone first received regulatory approval for the
treatment of adults with schizophrenia in May 2009 in the
USA, with subsequent approvals in Israel, Argentina, and
Mexico. The US FDA approval was based on two pivotal
short-term (4- and 6-week) acute trials [3, 6, 8]. In addition,
three 52-week maintenance studies have been conducted
using a non-inferiority design to compare outcomes in
individuals who were randomized and successfully stabi-
lized on either iloperidone or haloperidol [7]. The pooled
results demonstrated that the 52-week relapse rate for
iloperidone at a mean daily dose of 12.5 mg was compa-
rable to that for haloperidol 12.5 mg (52-week relapse
estimate by Kaplan–Meier [KM] method was 43.5 %
relapse for iloperidone vs. 41.2 % relapse for haloperidol).
From a statistical standpoint, iloperidone was non-inferior
to haloperidol within the margin stated in the study design
[7]. The study reported here (REPRIEVE [RElapse
PRevention, Iloperidone EVidence Evaluation]) was a
double-blind placebo-controlled randomized withdrawal
study with the primary objective of demonstrating that
continuation of iloperidone has statistically and clinically
significant relapse-prevention benefits during maintenance
phase therapy.
2 Methods
2.1 Overview of Design
Upon entering the study, subjects began taking iloperidone
in an open-label crossover design using a standard up-ti-
tration schedule to discontinue any prior antipsychotic
while simultaneously reaching the therapeutic target dose
of iloperidone 12 mg on a twice-daily regimen. Response
to iloperidone was then established by flexible-dose open-
label iloperidone treatment for at least 12 weeks. Follow-
ing stabilization, subjects entered the double-blind relapse-
prevention phase and were randomized 1:1 to either con-
tinue on the same flexible-dose regimen of iloperidone or
to stop iloperidone in favor of a matched placebo. Subjects
were followed for up to 26 weeks and were withdrawn
upon showing signs of relapse or upon conclusion of the
study, based on efficacy results following a predefined
interim analysis (IA). The primary endpoint was a com-
parison of the time until first relapse event between groups.
Secondary objectives included assessing the long-term
safety and tolerability of the flexible-dose iloperidone
regimen as well as the course of symptom response.
2.2 Patient Population
This was an international multicenter trial conducted at 66
study sites between 7 February 2011 and 21 March 2014:
USA – 27 sites (289 total subjects); India – 15 sites (118
total subjects), and Ukraine – 24 sites (228 total subjects).
Study subjects included men and women (aged
18–65 years, inclusive) with a Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV)
diagnosis of schizophrenia for at least 1 year, currently
treated as outpatients with a need for ongoing psychiatric
treatment, and who had a clinical reason for changing their
current antipsychotic medication. The objective of many
other key enrollment criteria was to establish a population
known to be vulnerable to relapse and have a history of
reasonable therapeutic response to first-line antipsychotics.
Therefore, subjects needed to have had a history of at least
one acute exacerbation of schizophrenia that was
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successfully treated. In addition, subjects with a history of
treatment-resistant schizophrenia based on a recent history
of poor response to two or more antipsychotic trials were
excluded, as were those with a high level of symptoms as
defined by a Positive and Negative Syndrome Scale
(PANSS) total score (PANSST) greater than 100. Other key
exclusion criteria included having a primary diagnosis
other than schizophrenia, being on iloperidone at the time
of the screening visit, being medically unstable, having a
history of serious suicidal ideation within the prior
6 months or suicidal behavior within the last 2 years, or
having a positive history of significant cardiovascular ill-
ness (e.g., myocardial infarction, cardiac arrhythmia) or
baseline QTcF C 450 ms. Included subjects had a body
mass index[17 and\40 kg/m2.
The study protocol and all amendments were reviewed
by either the Independent Ethics Committee or Institutional
Review Board for each center. The study was conducted
according to the ethical principles of the Declaration of
Helsinki. Informed consent was obtained from each subject
in writing before any study-specific procedures were
performed.
2.3 Study Phases
The study design consisted of three phases after baseline
screening: (1) an initial ‘‘cross-titration phase’’ with the
goal of changing from the previous antipsychotic to
iloperidone monotherapy, whereby the subject’s current
antipsychotic was discontinued; (2) a ‘‘stabilization phase’’
with the goal of establishing a clinically appropriate
iloperidone dose and meeting stabilization criteria for the
ensuing relapse-prevention phase; and (3) a double-blind
‘‘relapse-prevention phase,’’ where subjects were random-
ized to stay on or withdraw from iloperidone and followed
for up to 26 weeks until either showing signs of relapse or
reaching the final end-of-study (EOS) visit. These phases
are shown in the CONSORT (Consolidated Standards Of
Reporting Trials) flow diagram (Fig. 1) and described in
greater detail in the following sections. For the analysis,
data from the initial cross-titration and stabilization phases
were combined. Of note is that the Independent Data
Monitoring Committee (iDMC) reviewed the results of the
IA and determined that the study had successfully met its
efficacy endpoint. Once the iDMC’s decision was
announced, new patient enrollment stopped, and subjects
who had not completed the double-blind relapse-preven-
tion phase were discontinued after completing their next
(and final) study visit.
2.3.1 Initial Cross-Titration Phase
Consenting subjects meeting inclusion/exclusion criteria
began an initial crossover to, or were started on, open-label
iloperidone tablets taken twice a day to reach a target dose
of 12 mg/day by day 4. The initial up-titration regimen was
fixed, whereby the doses were increased from
2 ? 4 ? 8 ? 12 mg/day. The dosage was then main-
tained at 12 mg/day for the following 3 days. The prior
antipsychotic had to be completely discontinued by day 4
of the initial iloperidone up-titration period, with the
specific down-titration schedule determined based on
investigator judgment.
All concomitant illnesses were treated in accordance
with prevailing medical practice. Subjects who were pre-
scribed other medications with known central nervous
system effects (e.g., anti-parkinsonian medications, beta-
blockers, anxiolytics, or sedative/hypnotics) for at least
6 weeks prior to entering the study were maintained at
these stable doses during the study. Per the protocol,
zolpidem was permitted throughout the study as a rescue
medication for insomnia; lorazepam was permitted as a
rescue medication for agitation, severe restlessness, or
insomnia; and anticholinergics were permitted for the
treatment of EPS.
2.3.2 Stabilization Phase
After reaching the target dose of 12 mg/day at the end of
the first week, subjects were evaluated weekly for the first
2 weeks and then every other week until meeting stabi-
lization or exclusion criteria. This phase lasted 14 weeks
unless the subject needed more time to meet randomization
criteria; thus, the stabilization phase could be extended for
a maximum of 24 weeks. During this time, the investigator
could adjust the iloperidone dose up or down in increments
of 4 mg/day based on clinical judgment, within a permitted
range of a total daily dose of 8–24 mg/day. Stability was
defined as reaching and remaining at a prespecified
symptom criteria threshold (e.g., Clinical Global Impres-
sion of Severity [CGI-S] B4, five individual PANSS pos-
itive symptoms [delusions, conceptual disorganization,
hallucinatory behavior, suspiciousness/persecution, hostil-
ity] and uncooperative item scores B4, as well as a
PANSST B70) and not requiring any new acute treatment
service intervention. Subjects needed to remain clinically
stable for at least 12 weeks and not require any dose
adjustments for at least 4 weeks before being eligible for
the relapse-prevention phase described next.
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2.3.3 Relapse-Prevention Phase
Subjects who met full stabilization criteria then entered the
relapse-prevention phase and were randomized on a 1:1
ratio (administered via an interactive voice response sys-
tem [IVRS]). Study drug and placebo were provided by the
sponsor with identical packaging, labeling, administration
schedule, appearance, taste, and odor. Subjects, investiga-
tors, individuals performing the assessments, and data
analysts remained blind to the identity of the treatment
from the time of randomization until database lock.
Subjects assigned to iloperidone remained on the same
dose as had been determined for stabilization. Any subse-
quent dose increase of double-blind study medication for
symptom control would automatically meet relapse crite-
ria, whereas dose reductions for tolerability issues were not
considered to be relapse criteria.
Subjects were evaluated weekly after randomization for
the first 4 weeks, every other week between weeks 5 and
14, and then every 4 weeks for up to a maximum of
26 weeks. Each study visit after randomization included an
assessment to see whether the subject met relapse criteria,
and subjects and caregivers were asked to notify study staff
immediately in the event of any signs of impending relapse
that began between study visits. Subjects who met relapse
criteria were considered to have met the study endpoint
criteria, received an EOS assessment, and then received
standard of care treatment for schizophrenia. Other reasons
for early discontinuation included subject withdrawal and
sponsor-initiated termination after the IA decision to end
the study early (see Sect. 2.4).
2.4 Efficacy Assessments
The primary efficacy endpoint was time to relapse or
impending relapse, defined as any of the following: hospi-
talization due to worsening of schizophrenia; increase
(worsening) of the PANSST of C30 % from randomization,
PANSST score confirmed at a second visit conducted within
1–7 days; clinically significant emergent or worsening sui-
cidal, homicidal, or aggressive behavior; a CGI-Improve-
ment (CGI-I) score of 6 (muchworse) or 7 (verymuchworse)
after randomization; a dose increase in study medication or a
need for additional open-label antipsychotic treatment.
A pre-specified IA was to be performed by the iDMC
after 60 events (relapse or impending relapse) had
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Fig. 1 CONSORT (Consolidated Standards of Reporting Trials) flow diagram of study design
738 P. J. Weiden et al.
occurred. If significant efficacy was observed (at 0.001 a
level), the study was considered to have met the research
endpoint. At that point, further enrollment of new subjects
and follow-up of enrolled subjects would be halted.
Secondary efficacy variables included the change from
randomization to endpoint for PANSST and subscale
(positive, negative, and general psychopathology) scores,
18-item Brief Psychiatric Rating Scale (BPRS), CGI-I,
CGI-S and the Sheehan Disability Scale (SDS).
2.5 Safety Assessments
Safety assessments were conducted throughout all phases
of the study and included collection of adverse events
(AEs), clinical laboratory evaluations, 12-lead electrocar-
diograms (ECGs), body weight, vital signs, Columbia
Suicide Severity Rating Scale (C-SSRS), and movement
disorder rating scales (Barnes Akathisia Rating Scale
[BARS], Abnormal Involuntary Movement Scale [AIMS],
and Simpson Angus Scale [SAS]).
2.6 Statistical Analyses
2.6.1 Analyses Performed
Sample size calculation was based on the primary endpoint
of time to relapse using a 2-sided log rank test at the 0.048
level of significance, and a true hazard ratio (HR) of 1.8
(i.e., the hazard of the placebo group meeting relapse cri-
teria relative to the hazard of the iloperidone group meeting
relapse criteria).
The log-rank test was used to evaluate the primary
outcome of time to relapse or impending relapse between
the iloperidone and placebo groups. An independent bio-
statistics team conducted a predefined unblinded IA uti-
lizing a group sequential testing procedure with an
O’Brien–Fleming stopping boundary after 68 observed
events (relapse or impending relapse). Once those event
numbers were reached, additional time was needed for the
statistical team and the iDMC to prepare, analyze, and
communicate their decision to end the study. The final
dataset had more subjects with more events than the dataset
used for the IA. Studies that are halted because of an IA
review may present results in two ways: the data available
for the IA review and a final analysis, including the entire
data from all study visits and observations. Because the
study was stopped early as planned in the protocol as a
result of significance examined at a level of a = 0.001 in
the IA, results from the IA are considered to be the primary
results, and the final results (examined at an a = 0.048)
including the data between the IA and the actual ending are
considered supportive. Plots of KM product limit estimates
were used to summarize the survival distributions. In
addition, a Cox regression model was used to provide an
estimated HR and corresponding 95 % confidence interval
(CI).
Change from baseline at randomization for the sec-
ondary efficacy variables such as PANSS total and subscale
scores, 18-item BPRS, SDS, CGI-I, and CGI-S was ana-
lyzed using an analysis of covariance (ANCOVA) model
with treatment and site as main effects and the score at
randomization as a covariate. The treatment-by-site inter-
action and treatment by baseline interaction were tested
and analyzed only in an ad hoc exploratory fashion. No
adjustment for multiple comparisons was made.
Efficacy in the control of symptoms analysis was based
on all randomized subjects who received at least one dose
of blinded study medication and from whom at least one
efficacy measurement was obtained while on study medi-
cation. The safety population was defined for both the
combined initial cross-titration and stabilization phases and
the relapse-prevention phase. For each phase, the safety
population included all subjects who received at least one
dose of study medication during the corresponding phase.
Descriptive statistics by study phase for each of the safety
assessments were calculated. Conclusions on the secondary




The final analysis dataset consisted of 635 subjects entering
the stabilization phase, with 303 (48 %) entering the relapse-
prevention phase, including 153 subjects randomized to
continue with iloperidone and 150 to switch to placebo. The
IA data consisted of 587 subjects entering the stabilization
phase, with 195 (33 %) continuing on in the relapse-pre-
vention phase. Of those 195 subjects, 99 were randomized to
continue with iloperidone and 96 discontinued iloperidone
but continued taking matched placebo (Fig. 1).
Demographic data are presented for the final analysis
(Table 1). Distribution of subjects by age, sex, race, and
baseline PANSS scores was balanced in the iloperidone
and placebo treatment groups. At the time of the first
screening visit, the majority (90 %) of study participants
reported taking antipsychotic medications for the treatment
of schizophrenia. Data for the IA are available in the
Electronic Supplementary Material.
3.2 Dosing
The modal total daily dose for iloperidone during the
combined initial cross-titration and stabilization phase
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and the subsequent relapse-prevention phase based on
the final analysis was 12 mg in each. The average total
daily dose for iloperidone during the combined initial
cross-titration and stabilization phase and subsequent
relapse-prevention phase was 13.6 ± 4.5 mg (Fig. 2)
and 15.0 ± 4.9 mg, respectively.
3.3 Primary Efficacy
3.3.1 Relapse Prevention
The IA was completed after a total of 68 relapse events. As
mentioned, because results met the study hypothesis that
continuation on iloperidone is more effective for relapse
prevention than placebo, the iDMC recommended the
study be stopped.
The IA showed that continued iloperidone treatment was
more effective than placebo in relapse prevention (log rank
test: p\ 0.0001), with estimated 26-week relapse rates of
63.4 % (KM estimate; 95 % CI 52.7–74.1) for the placebo
group compared with 20.4 % (KM estimate; 95 % CI
12.9–31.4) for those continuing with iloperidone. The
mean time to relapse based on KM estimates was 71 days
for placebo and 139 days for iloperidone, with a Cox
regression HR estimate of 4.7 (95 % CI 2.7–8.3) favoring
iloperidone (p\ 0.0001) (Fig. 3a; Table 2).
The supportive final analysis confirmed the IA results
favoring iloperidone; the time to relapse or impending
relapse was significantly longer by the log-rank test
(p\ 0.0001) for the iloperidone treatment group than for
the placebo treatment group (140 and 95 days, respec-
tively) (Fig. 3b). The relapse rate was lower in the
iloperidone treatment group than in the placebo treatment
Fig. 2 Average iloperidone total daily dose during the initial cross-
titration and stabilization phase
Table 1 Demographic summary by treatment group: final analysis, enrolled/randomized subjects









Age (years) 39.6 ± 11.3 38.4 ± 11.3 38.2 ± 11.1 38.3 ± 11.2
Male sex 400 (63.0) 96 (62.7) 82 (54.7) 178 (58.7)
BMI (kg/m2) 26.8 ± 5.6 26.5 ± 5.5 25.6 ± 5.5 26.1 ± 5.5
Race
Caucasian 280 (44.1) 74 (48.4) 77 (51.3) 151 (49.8)
Black 201 (31.7) 31 (20.3) 28 (18.7) 59 (19.5)
Asian 123 (19.4) 38 (24.8) 40 (26.7) 78 (25.7)
Pacific Islander 2 (0.3) 1 (0.7) 0 1 (0.3)
Other 29 (4.6) 9 (5.9) 5 (3.3) 14 (4.6)
Age at diagnosis (years) 26.0 ± 8.7 25.4 ± 8.7 26.5 ± 8.8 25.9 ± 8.8
PANSST at baseline
a 76.8 ± 11.6 55.6 ± 10.8 55.2 ± 10.1 55.3 ± 10.4
CGI-S, last study visit, Nb,c – 112 105 217
CGI-S – 3.0 ± 0.9 3.6 ± 1.1 –
Data are presented as mean ± standard deviation or n (%) unless otherwise indicated
BMI body mass index, DBRP double-blind RP, CGI-S Clinical Global Impression of Severity, PANSST Positive and Negative Syndrome Scale
Total Score, RP relapse prevention
a Baseline at the beginning of the respective phase
b Percentages are based on the total number of subjects with available data in each treatment group
c RP completion visit includes observations from last visit during DBRP period for subjects who completed the study and RP completion visit
that could not be remapped to a previous scheduled visit for subjects who discontinued the DBRP phase
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group (17.9 vs. 64.0 %, respectively; p < 0.0001). The
demonstrated HR estimate was 5.2 (95 % CI 3.2–8.4).
The IA of time to relapse after 68 events was supported
by the results of the final analysis, which included the
entire efficacy data collected in the study, after a total of
104 events (Fig. 3b).
3.4 Symptoms and Severity of Illness Results
The secondary efficacy results for course of symptoms
(PANSST) and overall severity of illness (CGI-S) used the
final analysis dataset and are presented in Table 2. Evalu-
ation of the PANSST demonstrated a significantly smaller
Fig. 3 Kaplan–Meier plots of
time to relapse or impending
relapse. a Interim analysis
population (N = 195). Interim
analysis mean time to relapse:
placebo 71 days, iloperidone
139 days; interim analysis Cox
regression hazard ratio estimate:
4.7 (95 % confidence interval
2.7–8.3; p\ 0.0001, log-rank
test). b Final analysis
population. Final analysis mean
time to relapse: placebo
95 days; iloperidone 140 days;
final analysis Cox regression
hazard ratio estimate: 5.2 (95 %
confidence interval 3.2–8.4;
p\ 0.0001, log-rank test).
Survival estimates are displayed
with 95 % Hall–Wellner
confidence bands in color
shading. The primary efficacy
endpoint—time to relapse or
impending relapse—is defined
as the time from the first dose of
double-blind study medication
to the assessment at which the
first time relapse or impending
relapse is identified. For
subjects not relapsing, the time
to relapse is censored to the last
double-blind relapse-prevention
period study visit, including the
end of study visit, early
termination visit, or
unscheduled visit for the
double-blind relapse-prevention
period. Two subjects lost to
follow-up after randomization
were excluded from the analysis
population
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increase (least squared mean change in the ANCOVA
model) from the relapse-prevention baseline to the last
study visit in the iloperidone treatment group (1.1) com-
pared with the placebo treatment group (12.4; p\ 0.0001).
Similar results were observed based on the same parame-
ters for the 18-item BPRS (iloperidone group 4.2; placebo
group 12.1; p\ 0.0001).
The median CGI-S score was 3.0 (i.e., mildly ill) for the
iloperidone treatment group and 4.0 (i.e., moderately ill)
for the placebo treatment group at the last study visit (final
analysis). No statistically significant differences occurred
between the iloperidone and placebo groups on the CGI-S.
The median SDS total score at the last study visit was
8.0 for the iloperidone treatment group and 9.0 for placebo-
treated subjects. The least squared mean change from
relapse-prevention baseline to the last study visit was sig-
nificantly lower in the iloperidone treatment group (–0.2)
than in the placebo treatment group (1.8; p = 0.0062, last
observation carried forward) (Table 2).
Table 2 Secondary efficacy
variables: cross-titration/
stabilization and relapse-








PANSS total score, change from baseline to last visit
N 607 150 149
Baseline mean (SD) 76.8 (11.54) 55.6 (10.76) 55.2 (10.08)
Change mean (SE) -14.0 (14.05) 1.1 (1.12)* (Adj) 12.4 (1.15) (Adj)
CGI-S, last visit
N 609 112 105
Median 3.0 3.0 4.0
SDS total score, change from baseline to last visit
N 586 142 128
Baseline mean (SD) 15.6 (7.42) 8.8 (6.47) 8.0 (6.31)
Change mean (SE) -4.6 (7.62) -0.2 (0.54)** (Adj) 1.8 (0.61) (Adj)
OC data from the safety set are presented for the PANSS in the cross-titration/stabilization phase; LOCF
data are presented for the PANSS and SDS for the relapse-prevention phase. The CGI-S reflects OC data, as
this measure does not include a baseline assessment. Baseline refers to the respective study phases shown at
the top of each column that displays data. Cross-titration/stabilization baseline is defined as the last
available assessment prior to the start of medication in the cross-titration phase. Relapse prevention
baseline is defined as the last available assessment prior to the first dose of double-blind study medication.
Change from cross-titration/stabilization baseline is calculated as post value minus cross-titration/stabi-
lization baseline value. A negative change indicates improvement. Change from relapse prevention baseline
is calculated as post value minus relapse prevention baseline value. A negative change indicates
improvement. P values are based on an ANCOVA model with treatment and site as main effects and
relapse prevention baseline as a covariate. Adjusted change is the least squared mean change obtained from
the ANCOVA model
Adj adjusted, ANCOVA analysis of covariance, CGI-S Clinical Global Impression of Severity, LOCF last
observation carried forward, OC observed cases, PANSS Positive and Negative Syndrome Scale, SD
standard deviation, SDS Sheehan Disability Scale, SE standard error
* p\ 0.0001, ** p = 0.0062, log-rank test
Table 3 Incidence of treatment-emergent adverse events (5 % inci-
dence in any group): cross-titration and stabilization phase
Adverse event Total (N = 629)
Subjects with at least one TEAE 433 (68.8)
Possibly drug-related TEAE 345 (54.8)





Weight increased 34 (5.4)
Nausea 32 (5.1)
Somnolence 52 (8.3)
Dry mouth 43 (6.8)
Data are presented as n (%)
TEAE treatment-emergent adverse event
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3.5 Safety
3.5.1 Adverse Events Overview
Cross-titration and stabilization phase Of the 629 subjects
who had some exposure to open-label iloperidone during
these combined phases, 433 (69 %) experienced a treat-
ment-emergent AE (TEAE) (Table 3), of which 345
TEAEs were suspected to be related to study drug. The
most common TEAEs (C5 %) suspected to be related to
study drug were dizziness (10.7 %), somnolence (8.1 %),
and dry mouth (6.7 %). A total of 21 subjects (3.3 %)
treated with iloperidone experienced a serious AE (SAE).
The SAE was considered to be possibly attributed to study
drug for 33 % of these subjects. The most common SAE
was schizophrenia (1.4 %). No other SAEs occurred in
more than one subject. Two subjects in the study died
while receiving iloperidone (one in each phase). The death
during the titration and stabilization phase was attributed to
alcohol poisoning and was considered unrelated to study
medication.
Relapse-prevention phase A total of 60 of the 151 subjects
who continued on double-blind iloperidone and 54 of the
150 who went on to placebo (36.0 %) experienced a TEAE
(Table 4). During the relapse-prevention phase, 23.3 % of
all subjects had at least one TEAE that was suspected to be
related to study drug; the percentage of subjects with at
least one TEAE suspected to be related to study drug was
similar between treatment groups. No TEAEs suspected to
be related to study drug had an incidence C5 % in the
iloperidone treatment group. Six subjects (4.0 %) treated
with iloperidone versus four (2.7 %) treated with placebo
experienced an SAE. As in the previous phase, the most
common SAE was schizophrenia: 1.3 % in iloperidone-
treated subjects and 1.3 % in placebo-treated subjects. No
other SAEs occurred in more than one subject. The second
case of death in the study occurred in the relapse-preven-
tion phase and involved a 47-year-old female whose cause
of death was initially labeled as ‘‘unknown’’; conse-
quently, the investigator assigned a potentially causal
relationship to study drug. The subject’s final cause of
death was reported as ‘‘probable sudden cardiac arrhyth-
mia/natural’’. Of note, a routine ECG recorded the day
before her death was rated as unchanged from baseline,
with a QTcF of 410 ms.
3.5.2 Akathisia and Extrapyramidal Disorder
Cross-titration and stabilization phase Akathisia at base-
line prior to starting iloperidone and defined by a BARS
score C1 was present in 7 % of subjects; however, by the
end of the stabilization phase it was present in only 3 % of
subjects receiving open-label iloperidone. A total of 23
subjects (3.7 %) reported akathisia as a TEAE at one point
during this phase while receiving open-label iloperidone.
A total of 16 subjects (2.5 %) reported extrapyramidal
disorder as a TEAE. Subjects’ mean SAS total score,
reflecting neuroleptic-induced parkinsonism was 0.8 at
initial baseline prior to starting the iloperidone crossover.
After stabilization on iloperidone, the mean SAS score was
0.5. No clinically meaningful changes in dyskinesia scores
as measured by the AIMS were observed (range 0.4–0.6).
Relapse-prevention phase One subject (1 %) treated with
iloperidone versus 0 treated with placebo reported akathisia
as a TEAE during the relapse-prevention phase. The rate of
akathisia in the placebo group (8 %) was greater than
reported in the iloperidone treatment group (5 %) at com-
pletion, according to the BARS (score C1).
Two subjects (1.3 %) treated with iloperidone versus 0
treated with placebo reported extrapyramidal disorder as a










Subjects with at least one TEAE 60 (39.7) 54 (36.0) 114 (37.9)
Possibly drug-related TEAE 37 (24.5) 33 (22.0) 70 (23.3)
Subjects with one or more serious TEAE 6 (4.0) 4 (2.7) 10 (3.3)
Schizophrenia 3 (2.0) 15 (10.0) 18 (6.0)
Insomnia 3 (2.0) 7 (4.7) 10 (3.3)
Dizziness 4 (2.6) 4 (2.7) 8 (2.7)
Headache 3 (2.0) 5 (3.3) 8 (2.7)
Weight increased 2 (1.3) 4 (2.7) 6 (2.0)
Nausea 2 (1.3) 0 2 (0.7)
Somnolence 2 (1.3) 0 2 (0.7)
Dry mouth 0 0 0
Data are presented as n (%)
TEAE treatment-emergent adverse event
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TEAE. Mean SAS total scores were 0.3 and 0.4 for
iloperidone and placebo subjects, respectively, at comple-
tion. No clinically meaningful changes in the AIMS scores
were observed (range 0.2–0.4). Medications for EPS
included trihexyphenidyl (iloperidone 4.6 %; placebo
4.0 %), benzatropine (0.7 % in both treatment groups), and
diphenhydramine (iloperidone 0.7 %; placebo 2.0 %).
3.5.3 Clinical Laboratory Parameters
Two clinically notable differences in hematology or
chemistry parameters occurred: 4.5 and 2.6 % of subjects
treated with iloperidone had elevations in blood urea
nitrogen levels and low-density lipoprotein (LDL),
respectively, versus 0 in subjects treated with placebo.
3.5.4 Weight
Cross-titration and stabilization phase Mean change from
baseline in weight at the end of the cross-titration and
stabilization phase was 0.7 kg in subjects treated with
iloperidone; 13.6 % of subjects treated with iloperidone
experienced a C7 % increase in weight from baseline at the
end of this phase, and 3.4 % experienced a C7 % decrease
in weight over the same period. Increased weight reported
as an AE occurred in 5.4 % of subjects during the phase.
Relapse-prevention phase Mean change from baseline in
weight from the initial study baseline to the end of the
study was 0.02 kg in subjects treated with iloperidone
versus 0.73 kg in subjects treated with placebo, whereas
25.2 % of subjects treated with iloperidone versus 20 % of
subjects treated with placebo experienced a C7 % increase
in weight from initial baseline at the end of the study. In
total, 12.6 % of iloperidone subjects and 10.7 % of placebo
subjects experienced a decrease in weight of C7 % from
initial baseline measurements. Increased weight reported as
an AE occurred in 1.3 % of iloperidone subjects and 2.7 %
of placebo subjects in this phase. No notable between-
group differences in waist circumference were observed at
the end of the study.
3.5.5 Cardiovascular Parameters
Cross-titration and stabilization phase Mean change from
baseline in QTcF for subjects treated with iloperidone was
6.4 ms. One subject had a QTcF[ 500 ms (baseline
QTcF: 412.7 ms), and six subjects (1.0 %) had an increase
from baseline in QTcF C 60 ms, the protocol-specified
criterion for discontinuation.
Relapse-prevention phase The mean change from baseline
in QTcF for subjects treated with iloperidone was 4.9
versus 1.0 ms in subjects treated with placebo. No subjects
in this phase had an increase from baseline in
QTcF C 60 ms or a QTcF[ 500 ms.
4 Discussion
Consistent with results of earlier studies comparing
iloperidone with haloperidol, iloperidone therapy is effec-
tive for maintenance-phase treatment of schizophrenia [7].
Continuing on iloperidone therapy was statistically and
clinically effective in preventing relapse. Subjects stabi-
lized on iloperidone who were subsequently randomized to
placebo withdrawal were three times more likely to relapse
than individuals continuing to receive the medication.
Furthermore, iloperidone showed statistical and clinical
benefits in delaying the time until relapse relative to pla-
cebo among the subgroup of subjects who did eventually
relapse. On the basis of the observed early efficacy at the
preplanned IA, the iDMC recommended an early stop for
the trial. The final analysis confirmed the efficacy
demonstrated at the interim.
Results of the analyses for psychiatric symptoms and
illness severity support the robust relapse-prevention find-
ings. Subjects randomized to iloperidone during the
relapse-prevention phase continued to maintain their
symptom response achieved in the stabilization phase.
Additionally, the adjusted mean CGI-S scores indicated
that subjects in the iloperidone treatment group were
mildly ill, whereas subjects in the placebo treatment group
were moderately ill.
The average daily dose for iloperidone-treated subjects
across study phases in this trial was 12–16 mg, with a
modal dose for both the initial cross-titration/stabilization
and relapse-prevention phases of 12 mg/day. Given that
investigators were permitted to treat patients by optimizing
iloperidone dose during stabilization with a dose range
between 12 and 24 mg, it seems that investigators judged
the 12- to 16-mg dose range as optimal for most subjects.
The alternative hypothesis of dose-related AEs presenting a
tolerability ceiling of 16 mg was also considered, but it
seems unlikely given that the majority of those subjects
receiving a dose[16 mg/day did not down-titrate iloperi-
done during the trial. Data from an earlier pharmacoki-
netic/pharmacodynamic modeling study of the dose–
response characteristics of iloperidone suggests there is, in
fact, a therapeutic response association with plasma con-
centrations between 5 and 8 ng/ml without any further
efficacy at higher plasma levels [9]. The iloperidone dosage
range that typically results in this plasma concentration is
12–16 mg/day.
Further, the relative absence of dose escalation in this
report of the REPRIEVE study suggests that, within the
parameters of the study population, 12–16 mg is a
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reasonable initial target dose for schizophrenia outpatients
who are starting on iloperidone. The caveat is that treat-
ment-resistant patients were excluded such that the clinical
dosing inference cannot be generalized to choosing a target
dose for relatively treatment-resistant patients.
The safety and tolerability profile characterized by the
3210 subjects exposed to iloperidone across nine studies in
the clinical trials program is reinforced by the current study
and is consistent with those in other iloperidone trials
[10–12]. The most common AE was dizziness, occurring in
11.6 % of the subjects during the initial cross-titration and
stabilization phase. As expected, the incidence of dizziness
was much lower during the relapse-prevention phase
(2.6 %), presumably due to accommodation of a1 antag-
onism. A recently reported switch study using iloperidone
also demonstrated that the AEs associated with a1 antag-
onism were transient in nature [10, 11]. Reported somno-
lence was also less frequent during the relapse-prevention
phase relative to the stabilization period. Rates of
schizophrenia (worsening or exacerbation) as a TEAE were
constant in subjects receiving iloperidone across the trial.
As expected, for subjects randomized to placebo, these
rates increased during the relapse-prevention phase.
No new safety concerns with long-term use of iloperi-
done appeared in the analysis. Any observed laboratory
abnormalities were expected based on those reported in
previous clinical studies. Although increases in the QTc
interval were more common in the iloperidone treatment
group than in the placebo treatment group, this is not
surprising given that iloperidone is known to have some
propensity to lengthen the interval [1]. In the initial cross-
titration and stabilization phase, the mean change from
baseline in QTcF for subjects treated with iloperidone was
6.4 ms; in the relapse-prevention phase, the mean change
from baseline in QTcF for subjects treated with iloperidone
was 4.9 versus 1.0 ms in subjects treated with placebo. The
change in QTcF from baseline was slightly lower than that
observed in previous iloperidone studies [5, 7]. A possible
explanation for this finding may be the exclusion of sub-
jects with baseline QTc values C450 ms.
Results of the REPRIEVE trial support the minimal
impact of iloperidone on rates of common neurological
AEs associated with antipsychotic treatment (akathisia,
EPS), and its modest association with sedation and changes
in body weight and metabolic variables demonstrated in
previous research [1, 3, 6, 7, 10, 11]. The prevalence rate
for akathisia associated with iloperidone use is likely very
low; iloperidone appears to be associated with some of the
lowest rates of occurrence among currently available
atypical antipsychotic agents [13]. Akathisia causes pro-
found suffering in patients and, in extreme cases, is asso-
ciated with suicide [14]. Akathisia is also associated with
poor response to acute treatment, as well as treatment
withdrawal [15, 16]. Furthermore, akathisia is notoriously
difficult to diagnose and often is missed in clinical practice
[17, 18]. While the molecular basis for the low EPS and
akathisia profile is unknown, one hypothesis is that the very
high a1 antagonism in the CNS reverses the adverse effects
of striatal D2 receptor blockade [19].
Another feature of the iloperidone safety profile is rel-
atively modest effects associated with AEs not related to
movement disorders. Iloperidone is unique in that other
antipsychotic options with very low rates of EPS or aka-
thisia tend to be more likely to cause sedation and dys-
lipidemia. For the subjects receiving iloperidone in the
current trial, rates of sedation were 3.7 % in the cross-
titration and stabilization phase and decreased to 1.3 % for
iloperidone versus 0.7 % for placebo during the double-
blind phase. Total and LDL cholesterol levels and
triglycerides were reduced or unchanged in those receiving
iloperidone across all phases of the study. In the relapse-
prevention phase, more subjects with baseline elevated
total cholesterol values shifted to normal values while
taking iloperidone relative to placebo. Similarly, the
longer-term iloperidone treatment reported here had no
medically relevant impact on glucose levels.
The mean change in weight from the start of open-label
therapy to the last study visit was 0.02 kg for randomized
subjects continuing on iloperidone and 0.73 kg for those
randomized to placebo, with most change occurring during
cross-titration and stabilization. Increased weight reported
as an AE occurred in 5.4 % of subjects receiving iloperi-
done during cross-titration and stabilization and occurred
less frequently for iloperidone subjects than for placebo
subjects during the relapse-prevention phase (1.3 and
2.7 %, respectively). During the double-blind phase, mean
weight decreased slightly for subjects in both treatment
groups. Looking across all phases of the study, it appears
that starting iloperidone is associated with modest weight
gain during stabilization, but the overall trajectory of
weight changes seems to plateau by the time the subjects
enter the relapse-prevention phase of the study.
Iloperidone would be helpful in several clinical cir-
cumstances. For many patients with persistent symptoms,
iloperidone represents an efficacious medication to which
they have not yet been exposed. Because akathisia, EPS,
sedation, and metabolic derangements remain very signif-
icant problems, even in the era of atypical antipsychotics,
iloperidone may be selected on the basis of its overall
favorable tolerability profile. Furthermore, when a need
exists for switching medications, either by down-titrating a
current drug or by directly changing it, iloperidone may be
used flexibly, with either cross-titration or immediate
switch strategies. The results of the present study support
these observations. The choice of medication in these sit-
uations would need to be balanced with a potentially
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inconvenient twice-daily dosing regimen, need for titration
to avoid orthostatic hypotension, and considerations around
QT interval prolongation.
5 Limitations
The primary limitation of the study design is that the length
of the placebo-controlled phase of the study lasted for only
6 months. However, ethical considerations around the use
of placebo in this patient population necessarily informed
the study design. While the flexible-dosing regimen in this
study allowed for a more real-world experience, it also
prevented the assessment of dose–response.
6 Conclusions
The REPRIEVE study demonstrated that flexible dosing of
iloperidone for maintenance therapy (with a median dose
range of 12–16 mg/day) was safe and effective in pre-
venting relapse or impending relapse in subjects previously
stabilized on iloperidone. The analysis of safety indicated
no new safety signals with respect to the use of iloperidone.
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